379Rhodes DR, Ateeq B, Cao Q, et al. AGTR1 overexpression defi nes a subset of breast cancer and con-
fers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A. 2009;106:10284–9.
Rieger KE, Hong WJ, Tusher VJ, et al. Toxicity from radiation therapy associated with abnormal
transcriptional responses to DNA damage. Proc Natl Acad Sci U S A. 2004;101:6635–40.
Riemenschneider MJ, Hegi ME, Reifenberger G. MGMT promoter methylation in malignant glio-
mas. Target Oncol. 2010;5:161–5.
Romero Rosales K, Singh G, Wu K, et al. Sphingolipid-based drugs selectively kill cancer cells by
down-regulating nutrient transporter proteins. Biochem J. 2011;439:299–311.
Romero I, Garrido F, Garcia-Lora AM. Metastases in immune-mediated dormancy: a new oppor-
tunity for targeting cancer. Cancer Res. 2014;74:6750–7.
Rosell R. Mediating resistance in oncogene-driven cancers. N Engl J Med. 2013;368:1551–2.
Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in
lung cancer. NEJM. 2009;361:958–67.
Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifi es new prog-
nostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121:1403–12.
Röth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L)–telomerase-based cancer therapy.
Recent Results Cancer Res. 2010;184:221–34.
Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-defi cient mammary
tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc
Natl Acad Sci U S A. 2008;105:17079–84.
Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway
inhibitor GDC-0449. NEJM. 2009;361:1173–8.
Rummel S, Varner E, Shriver CD, Ellsworth RE. Evaluation of BRCA1 mutations in an unselected
patient population with triple-negative breast cancer. Breast Cancer Res Treat. 2013;137:
119–25.
Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer
through next-generation sequencing. J Clin Invest. 2011;121:3810–8.
Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with
protracted topotecan administration using a pharmacokinetically guided dosing approach. J
Clin Oncol. 2005;23:4039–47.
Saunders EJ, Dadaev T, Leongamornlert DA, et al. Fine-mapping the HOXB region detects com-
mon variants tagging a rare coding allele: evidence for synthetic association in prostate cancer.
PLoS Genet. 2014;10(2):e1004129.
Sebio A, Salazar J, Páez D, et al. EGFR ligands and DNA repair genes: genomic predictors of
complete response after capecitabine-based chemoradiotherapy in locally advanced rectal can-
cer. Pharmacogenomics J. 2015;15:77–83.
Schmieder AH, Winter PM, Caruthers SD, et al. Molecular MR imaging of melanoma angiogen-
esis with anb3-targeted paramagnetic nanoparticles. Magn Reson Med. 2005;53:621–7.
Scott KL, Kabbarah O, Lian MC, et al. GOLPH3 modulates mTOR signalling and rapamycin
sensitivity in cancer. Nature. 2009;459:1085–90.
Senzer N, Barve M, Kuhn J, et al. Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous
tumor cell” vaccine (FANG) in advanced cancer. Mol Ther. 2012;20:679–86.
Sequist LV, Nagrath S, Toner M, et al. The CTC-chip: an exciting new tool to detect circulating
tumor cells in lung cancer patients. J Thorac Oncol. 2009;4:281–3.
Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell
lung cancers into routine clinical practice. Ann Oncol. 2011;22:2616–24.
Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non–small-cell lung cancer. N
Engl J Med. 2014;370:1189–97.
Shore N, Concepcion R, Saltzstein D, et al. Clinical utility of a biopsy-based cell cycle gene
expression assay in localized prostate cancer. Curr Med Res Opin. 2014;30:547–53.
Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infi ltration
into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res.
2010;70:6171–80.
Silvestri A, Pin E, Huijber A, et al. Individualized therapy for metastatic colorectal cancer. J Intern
Med. 2013;274:1–24.
References